BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Rectal Cancer readouts · AssetMemo
X-WR-CALDESC:Upcoming phase 1/2 and later readouts in Rectal Cancer\, from 
 ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06640049-2162@assetmemo.bio
DTSTAMP:20261121T004107Z
DTSTART;VALUE=DATE:20271024
DTEND;VALUE=DATE:20271025
SUMMARY:Dostarlimab: Phase 2 readout est. (NCT06640049)
DESCRIPTION:Dostarlimab\, phase 2\, Rectal Cancer.\nStudy: A Study of Dosta
 rlimab in Participants With Untreated Locally Advanced Rectal Cancer in Ch
 ina\nEstimated primary completion: 24 October 2027. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/dostarlimab#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT06640049
URL:https://assetmemo.bio/drug/dostarlimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05239546-2162@assetmemo.bio
DTSTAMP:20261121T004107Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Dostarlimab: Phase 2 readout est. (NCT05239546)
DESCRIPTION:Dostarlimab\, phase 2\, Rectal Cancer.\nStudy: Single Arm Study
  of Neoadjuvant Dostarlimab in Stage II and III Deficient Mismatch Repair 
 Colon Cancers\nEstimated primary completion: 30 June 2028. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/dostarlimab#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT05239546
URL:https://assetmemo.bio/drug/dostarlimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07381777-2162@assetmemo.bio
DTSTAMP:20261121T004107Z
DTSTART;VALUE=DATE:20280701
DTEND;VALUE=DATE:20280702
SUMMARY:Dostarlimab: Phase 2 readout est. (NCT07381777)
DESCRIPTION:Dostarlimab\, phase 2\, Rectal Cancer.\nStudy: XELOX Plus DoSTA
 Rlimab Versus XELOX Alone as Consolidation Treatment After Standard Chemor
 adiation in pMMR/MSS or MSI-Low Locally Advanced Rectal Cancer (LARC) Pati
 ents\nEstimated primary completion: 1 July 2028. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/dostarlimab#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT07381777
URL:https://assetmemo.bio/drug/dostarlimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07740720-2162@assetmemo.bio
DTSTAMP:20261121T004107Z
DTSTART;VALUE=DATE:20300313
DTEND;VALUE=DATE:20300314
SUMMARY:Dostarlimab: Phase 3 readout est. (NCT07740720)
DESCRIPTION:Dostarlimab\, phase 3\, Rectal Cancer.\nStudy: A Study of the D
 uration of Dostarlimab in Untreated Mismatch Repair Deficient (dMMR)/ Micr
 osatellite Instability-high (MSI-H) Locally Advanced Rectal Cancer\nEstima
 ted primary completion: 13 March 2030. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/dostarlimab#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT07740720
URL:https://assetmemo.bio/drug/dostarlimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
